Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial
Trastuzumab emtansine reduced risk of death by 32% compared to the standard-of-care treatment arm of the trial. Findings being reported at the ESMO 2012 Congress ( European Society of Medical Oncology ) and published in New England Journal of Medicine . WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Marketing applications submitted for trastuzumab emtansine (T-DM1) in the US and Europe . Meaningful clinical data expected to be reported in coming year — for ImmunoGen compounds, T-DM1, and other partner compounds. ImmunoGen well positioned to advance its wholly owned compounds at least through
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the following presentations by Company management at upcoming
View HTML
Toggle Summary ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech , a member of the Roche Group, has disclosed that the U.S.
View HTML
Toggle Summary ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
— Dr. Morris brings to the Company extensive experience leading the successful development and registration of novel anticancer compounds — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody
View HTML
Toggle Summary ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that there will be clinical data presentations on two compounds that utilize
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Daniel Junius , President and CEO, will present at the upcoming
View HTML
Toggle Summary ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
Benefit seen in both lenalidomide-naïve and lenalidomide-refractory multiple myeloma WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today
View HTML
Toggle Summary Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Amgen has licensed the exclusive right to use the Company's
View HTML